quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:00:00·546d
PRRelease
INVO BioScience Inc. logo
NAYA Biosciences Inc. logo

NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma

INVO· INVO BioScience Inc.NAYA· NAYA Biosciences Inc.
Health Care
Original source

Companies

  • INVO
    INVO BioScience Inc.
    Health Care
  • NAYA
    NAYA Biosciences Inc.
    Health Care

Recent analyst ratings

  • Jan 19INVOUpdateMaxim Group$7.00
  • Aug 18INVOUpdateRoth Capital$5.25

Related

  • SEC358d
    NAYA Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities
  • SEC358d
    NAYA Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • SEC359d
    SEC Form 10-K filed by NAYA Biosciences Inc.
  • PR364d
    INVO Fertility Confirms New Nasdaq Trading Symbol of "IVF"
  • SEC370d
    NAYA Biosciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
  • PR374d
    NAYA Biosciences Announces Strategic Decision to Separate Fertility and Oncology Businesses into Distinct Operations – Company Renamed "INVO Fertility, Inc."
  • SEC374d
    NAYA Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
  • SEC388d
    SEC Form NT 10-K filed by NAYA Biosciences Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022